TCR2 Therapeutics Inc. (TCRR)
Stock Price:
$15.55 USD
-0.55 (-3.42%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
374.38M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-53.20M |
| Shares Out |
24.08M |
| EPS (ttm) |
-2.21 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$15.55 |
| Previous Close |
$16.10 |
| Change ($) |
-0.55 |
| Change (%) |
-3.42% |
| Day's Open |
16.34 |
| Day's Range |
15.34 - 16.34 |
| Day's Volume |
68,124 |
| 52-Week Range |
5.84 - 21.06 |
More Stats
| Market Cap |
374.38M |
| Enterprise Value |
247.85M |
| Earnings Date (est) |
Aug 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
24.08M |
| Float |
7.15M |
| EPS (basic) |
-2.1 |
| EPS (diluted) |
-2.21 |
| FCF / Share |
-2.13 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
725,679 |
| Short Ratio |
4.99 |
| Short % of Float |
4.50% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.57 |
| Revenue |
n/a |
| Operating Income |
-56.83M |
| Net Income |
-53.20M |
| Free Cash Flow |
-51.13M |
| Net Cash |
126.53M |
| Net Cash / Share |
5.26 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-20.23% |
| ROE |
-31.42% |
| ROIC |
-44.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$24.67*
(58.65% upside)
Low
16.0
Current: 15.55
High
35.0
Target: 24.67
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -51.38 | -26.45 | -13.18 | -9.92 |
| Net Income | -47.60 | -24.25 | -13.07 | -9.92 |
| Shares Outstanding | 21.10 | 0.62 | 0.37 | 0.28 |
| Earnings Per Share | -4.62 | -98.53 | -39.94 | -38.64 |
| Operating Cash Flow | -41.36 | -18.74 | -12.02 | -9.38 |
| Capital Expenditures | -3.88 | -1.02 | -0.39 | -0.87 |
| Free Cash Flow | -45.24 | -19.76 | -12.40 | -10.25 |
| Cash & Equivalents | 159 | 123 | 20.10 | 16.34 |
| Net Cash / Debt | 159 | 123 | 20.10 | 16.34 |
| Assets | 169 | 129 | 22.04 | 18.25 |
| Liabilities | 8.08 | 5.90 | 1.26 | 0.97 |
| Book Value | 160 | -85.70 | -26.32 | -11.88 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
TCR2 Therapeutics Inc. |
| Country |
United States |
| Employees |
87 |
| CEO |
Garry E. Menzel |
Stock Information
| Ticker Symbol |
TCRR |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: TCRR |
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include TC-210, mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which initiated in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies. Its product candidates in pipeline focuses on adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma areas. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.